Recombinant Thrombomodulin of Different Domains for Pharmaceutical, Biomedical, and Cell Transplantation Applications

Medicinal Research Reviews

Volumn 34, Issue 3, 2014, Pages 479-502

  Wang, Lin ^a   Jiang, Rui ^a   Sun, Xue Long ^a  

^a CLEVELAND STATE UNIVERSITY   (United States)

Author keywords

Anti inflammation; Antithrombosis; Endothelial cell; Recombinant; Thrombomodulin

Indexed keywords

RECOMBINANT THROMBOMODULIN;

ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL TRANSPLANTATION; DRUG INDICATION; HUMAN; NONHUMAN; PRIMATE; PROTEIN DOMAIN; PROTEIN FUNCTION; RODENT; THROMBOSIS;

ANTI-INFLAMMATION; ANTITHROMBOSIS; ENDOTHELIAL CELL; RECOMBINANT; THROMBOMODULIN;

ANIMALS; BIOMEDICAL TECHNOLOGY; HUMANS; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT PROTEINS; THROMBOMODULIN;

EID: 84897471311     PISSN: 01986325     EISSN: 10981128     Source Type: Journal    
DOI: 10.1002/med.21294     Document Type: Article

References (148)

1. Esmon CT, Owen WG. Identification of an endothelial cell cofactor for thrombin-catalyzed activation of protein C. Proc Natl Acad Sci USA 1981;78:2249-2252.
2. Esmon NL, Owen WG, Esmon CT. Isolation of a membrane-bound cofactor for thrombin-catalyzed activation of protein C. J Biol Chem 1982;257:859-864.
3. Maruyama I, Bell CE, Majerus PW. Thrombomodulin is found on endothelium of arteries, veins, capillaries, and lymphatics, and on syncytiotrophoblast of human placenta. J Cell Biol 1985;101:363-371.
4. Kawanami O, Jin E, Ghazizadeh M, Fujiwara M, Jiang L, Nagashima M, Shimizu H, Takemura T, Ohaki Y, Arai S, Gomibuchi M, Takeda K, Yu ZX, Ferrans VJ. Heterogeneous distribution of thrombomodulin and von Willebrand factor in endothelial cells in the human pulmonary microvessels. J Nippon Med Sch 2000;67:118-125.
5. Boffa MC, Burke B, Haudenschild CC. Preservation of thrombomodulin antigen on vascular and extravascular surfaces. J Histochem Cytochem 1987;35:1267-1276.
6. Raife TJ, Lager DJ, Madison KC, Piette WW, Howard EJ, Sturm MT, Chen Y, Lentz SR. Thrombomodulin expression by human keratinocytes. Induction of cofactor activity during epidermal differentiation. J Clin Invest 1994;93:1846-1851.
7. Conway EM, Nowakowski B. Biologically active thrombomodulin is synthesized by adherent synovial fluid cells and is elevated in synovial fluid of patients with rheumatoid arthritis. Blood 1993;81:726-733.
8. Mccachren SS, Diggs J, Weinberg JB, Dittman WA. Thrombomodulin expression by human blood monocytes and by human synovial tissue lining macrophages. Blood 1991;78:3128-3132.
9. Maillard C, Berruyer M, Serre CM, Amiral J, Dechavanne M, Delmas PD. Thrombomodulin is synthesized by osteoblasts, stimulated by 1, 25-(OH)2D3 and activates protein C at their cell-membrane. Endocrinology 1993;133:668-674.
10. Conway EM, Nowakowski B, Steinermosonyi M. Human neutrophils synthesize thrombomodulin that does not promote thrombin-dependent protein C activation. Blood 1992;805:1254-1263.
11. Jackson MT, Smith MM, Smith SM, Jackson CJ, Xue M, Little CB. Activation of cartilage matrix metalloproteinases by activated protein C. Arthritis Rheum 2009;60:780-791.
12. Wang L, Bastarache JA, Wickersham N, Fang X, Matthay MA, Ware LB. Novel role of the human alveolar epithelium in regulating intra-alveolar coagulation. Am J Respir Cell Mol Biol 2007;36:497-503.
13. Kawamura H, Hiramatsu Y, Watanabe I. Localization of thrombomodulin in a rabbit eye. Curr Eye Res 1996;15:938-942.
14. Yerkovich ST, Roponen M, Smith ME, McKenna K, Bosco A, Subrata LS, Mamessier E, Wikström ME, Le Souef P, Sly PD, Holt PG, Upham JW. Allergen-enhanced thrombomodulin (blood dendritic cell antigen 3, CD141) expression on dendritic cells is associated with a TH2-skewed immune response. J Allergy Clin Immunol 2009;123:209-216.
15. Isermann B, Hendrickson SB, Hutley K, Wing M, Weiler H. Tissue-restricted expression of thrombomodulin in the placenta rescues thrombomodulin-deficient mice from early lethality and reveals a secondary developmental block. Development 2001;128:827-838.
16. Isermann B, Sood R, Pawlinski R, Zogg M, Kalloway S, Degen JL, Mackman N, Weiler H. The thrombomodulin-protein C system is essential for the maintenance of pregnancy. Nat Med 2003;9:331-337.
17. Lohi O, Urban S, Freeman M. Diverse substrate recognition mechanisms for rhomboids: Thrombomodulin is cleaved by mammalian rhomboids. Curr Biol 2004;14:236-241.
18. Wu KK. Soluble thrombomodulin and coronary heart disease. Curr Opin Lipidol 2003;14:373-375.
19. Yamamoto S, Mizoguchi T, Tamaki T, Ohkuchi M, Kimura S, Aoki N. Urinary thrombomodulin, its isolation and characterization. J Biochem 1993;113:433-440.
20. Ito T, Maruyama I. Thrombomodulin: Protectorate God of the vasculature in thrombosis and inflammation. J Thromb Haemost 2011;9(Suppl 1):168-173.
21. Conway EM. Thrombomodulin and its role in inflammation. Semin Immunopathol 2012;34:107-125.
22. Anastasiou G, Gialeraki A, Merkouri E, Politou M, Travlou A. Thrombomodulin as a regulator of the anticoagulant pathway: Implication in the development of thrombosis. Blood Coagul Fibrinolysis 2012;23:1-10.
23. Suzuki K, Kusumoto H, Deyashiki Y, Nishioka J, Maruyama I, Zushi M, Kawahara S, Honda G, Yamamoto S, Horiguchi S. Structure and expression of human thrombomodulin, a thrombin receptor on endothelium acting as a cofactor for protein C activation. EMBO J 1987;6:1891-1897.
24. Weisel JW, Nagaswami C, Young TA, Light DR. The shape of thrombomodulin and interactions with thrombin as determined by electron microscopy. J Biol Chem 1996;271:31485-31490.
25. Van de Wouwer M, Plaisance S, De Vriese A, Waelkens E, Collen D, Persson J, Daha MR, Conway EM. The lectin-like domain of thrombomodulin interferes with complement activation and protects against arthritis. J Thromb Haemost 2006;4:1813-1824.
26. Conway EM, Van de Wouwer M, Pollefeyt S, Jurk K, Van Aken H, De Vriese A, Weitz JI, Weiler H, Hellings PW, Schaeffer P, Herbert JM, Collen D, Theilmeier G. The lectin-like domain of thrombomodulin confers protection from neutrophil-mediated tissue damage by suppressing adhesion molecule expression via nuclear factor kappaB and mitogen-activated protein kinase pathways. J Exp Med 2002;196:565-577.
27. Shi CS, Shi GY, Hsiao SM, Kao YC, Kuo KL, Ma CY, Kuo CH, Chang BI, Chang CF, Lin CH, Wong CH, Wu HL. Lectin-like domain of thrombomodulin binds to its specific ligand Lewis Y antigen and neutralizes lipopolysaccharide-induced inflammatory response. Blood 2008;112:3661-3670.
28. Delvaeye M, Noris M, De Vriese A, Esmon CT, Esmon NL, Ferrell G, Del-Favero J, Plaisance S, Claes B, Lambrechts D, Zoja C, Remuzzi G, Conway EM. Thrombomodulin mutations in atypical hemolytic-uremic syndrome. N Engl J Med 2009;361:345-357.
29. Geudens N, Van de Wouwer M, Vanaudenaerde BM, Vos R, Van De Wauwer C, Verleden GM, Verbeken E, Lerut T, Van Raemdonck DE, Conway EM. The lectin-like domain of thrombomodulin protects against ischaemia-reperfusion lung injury. Eur Respir J 2008;32:862-870.
30. Ikeguchi H, Maruyama S, Morita Y, Fujita Y, Kato T, Natori Y, Akatsu H, Campbell W, Okada N, Okada H, Yuzawa Y, Matsuo S. Effects of human soluble thrombomodulin on experimental glomerulonephritis. Kidney Int 2002;61:490-501.
31. Vasta GR, Quesenberry M, Ahmed H, O'Leary N. C-type lectins and galectins mediate innate and adaptive immune functions: Their roles in the complement activation pathway. Dev Comp Immunol 1999;23:401-420.
32. Huang HC, Shi GY, Jiang SJ, Shi CS, Wu CM, Yang HY, Wu HL. Thrombomodulin-mediated cell adhesion: Involvement of its lectin-like domain. J Biol Chem 2003;278:46750-46759.
33. Boffa MC, Karmochkine M. Thrombomodulin: An overview and potential implications in vascular disorders. Lupus 1998;7(Suppl):S120-S125.
34. Zhang Y, Weiler-Guettler H, Chen J, Wilhelm O, Deng Y, Qiu F, Nakagawa K, Klevesath M, Wilhelm S, Böhrer H, Nakagawa M, Graeff H, Martin E, Stern DM, Rosenberg RD, Ziegler R, Nawroth PP. Thrombomodulin modulates growth of tumor cells independent of its anticoagulant activity. J Clin Invest 1998;101:1301-1309.
35. Tsiang M, Lentz SR, Sadler JE. Functional domains of membrane-bound human thrombomodulin. EGF-like domain four to domain six and the serine/threonine-rich domain are required for cofactor activity. J Biol Chem 1992;267:6164-6170.
36. Wang W, Nagashima M, Schneider M, Morser J, Nesheim M. Elements of the primary structure of thrombomodulin required for efficient thrombin-activable fibrinolysis inhibitor activation. J Biol Chem 2000;275:22942-22947.
37. Wu C, Kim PY, Manuel R, Seto M, Whitlow M, Nagashima M, Morser J, Gils A, Declerck P, Nesheim ME. The roles of selected arginine and lysine residues of TAFI (Pro-CPU) in its activation to TAFIa by the thrombin-thrombomodulin complex. J Biol Chem 2009;284:7059-7067.
38. Hamada H, Ishii H, Sakyo K, Horie S, Nishiki K, Kazama M. The epidermal growth factor-like domain of recombinant human thrombomodulin exhibits mitogenic activity for Swiss 3T3 cells. Blood 1995;86:225-233.
39. Tohda G, Oida K, Okada Y, Kosaka S, Okada E, Takahashi S, Ishii H, Miyamori I. Expression of thrombomodulin in atherosclerotic lesions and mitogenic activity of recombinant thrombomodulin in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 1998;18:1861-1869.
40. Gerlitz B, Hassell T, Vlahos CJ, Parkinson JF, Bang NU, Grinnell BW. Identification of the predominant glycosaminoglycan-attachment site in soluble recombinant human thrombomodulin: Potential regulation of functionality by glycosyltransferase competition for serine474. Biochem J 1993;295:131-140.
41. Koyama T, Parkinson JF, Sie P, Bang NU, Mullerberghaus G, Preissner KT. Different glycoforms of human thrombomodulin. Their glycosaminoglycan-dependent modulatory effects on thrombin inactivation by heparin cofactor II and antithrombin III. Eur J Biochem 1991;198:563-570.
42. Elisen MG, von dem Borne PA, Bouma BN, Meijers JC. Protein C inhibitor acts as a procoagulant by inhibiting the thrombomodulin-induced activation of protein C in human plasma. Blood 1998;91:1542-1547.
43. De Cristofaro R, De Candia E, Landolfi R. Effect of high- and low-molecular-weight heparins on thrombin-thrombomodulin interaction and protein C activation. Circulation 1998;98:1297-1301.
44. Honda G, Masaki C, Zushi M, Tsuruta K, Sata M, Mohri M. The roles played by the D2 and D3 domains of recombinant human thrombomodulin in its function. J Biochem 1995;118:1030-1306.
45. Teasdale M, Bird CH, Bird P. Internalization of the anticoagulant thrombomodulin is constitutive and does not require a signal in the cytoplasmic domain. Immunol Cell Biol 1994;72:480-488.
46. Conway EM, Nowakowski B, Steinermosonyi M. Thrombomodulin lacking the cytoplasmic domain efficiently internalizes thrombin via nonclathrin-coated, pit-mediated endocytosis. J Cell Physiol 1994;158:285-298.
47. Conway EM, Pollefeyt S, Cornelissen J, DeBaere I, Steiner-Mosonyi M, Weitz JI, Weiler-Guettler H, Carmeliet P, Collen D. Structure-function analyses of thrombomodulin by gene-targeting in mice: The cytoplasmic domain is not required for normal fetal development. Blood 1999;93:3442-3450.
48. Healy AM, Rayburn HB, Rosenberg RD, Weiler H. Absence of the blood-clotting regulator thrombomodulin causes embryonic lethality in mice before development of a functional cardiovascular system. Proc Natl Acad Sci USA 1995;92:850-854.
49. Esmon CT. Thrombomodulin as a model of molecular mechanisms that modulate protease specificity and function at the vessel surface. FASEB J 1995;9:946-955.
50. Stearns DJ, Kurosawa S, Esmon CT. Microthrombomodulin. Residues 310-486 from the epidermal growth factor precursor homology domain of thrombomodulin will accelerate protein C activation. J Biol Chem 1989;264:3352-3356.
51. Bajzar L, Morser J, Nesheim M. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. J Biol Chem 1996;271:16603-16608.
52. Bajzar L, Manuel R, Nesheim ME. Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor. J Biol Chem 1995;270:14477-14484.
53. Nesheim M, Wang W, Boffa M, Nagashima M, Morser J, Bajzar L. Thrombin, thrombomodulin and TAFI in the molecular link between coagulation and fibrinolysis. Thromb Haemost 1997;78:386-391.
54. Murakami K, Okajima K, Uchiba M, Johno M, Nakagaki T, Okabe H, Takatsuki K. Activated protein C prevents LPS-induced pulmonary vascular injury by inhibiting cytokine production. Am J Physiol 1997;272:L197-L202.
55. Taylor FB, Jr, Chang AC, Esmon CT, Hinshaw LB. Baboon model of Escherichia coli sepsis: Description of its four stages and the role of tumor necrosis factor, tissue factors, and the protein C system in septic shock. Curr Stud Hematol Blood Transfus 1991;58:8-14.
56. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ, Jr. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699-709.
57. Li J, Garnette CS, Cahn M, Claytor RB, Rohrer MJ, Dobson JG, Jr, Gerlitz B, Cutler BS. Recombinant thrombomodulin inhibits arterial smooth muscle cell proliferation induced by thrombin. J Vasc Surg 2000;32:804-813.
58. Waugh JM, Li-Hawkins J, Yuksel E, Kuo MD, Cifra PN, Hilfiker PR, Geske R, Chawla M, Thomas J, Shenaq SM, Dake MD, Woo SL. Thrombomodulin overexpression to limit neointima formation. Circulation 2000;102:332-337.
59. Olivot JM, Estebanell E, Lafay M, Brohard B, Aiach M, Rendu F. Thrombomodulin prolongs thrombin-induced extracellular signal-regulated kinase phosphorylation and nuclear retention in endothelial cells. Circ Res 2001;88:681-687.
60. Hosaka Y, Higuchi T, Tsumagari M, Ishii H. Inhibition of invasion and experimental metastasis of murine melanoma cells by human soluble thrombomodulin. Cancer Lett 2000;161:231-240.
61. Griffin JH, Fernandez JA, Gale AJ, Mosnier LO. Activated protein C. J Thromb Haemost 2007;5:73-80.
62. Riewald M, Petrovan RJ, Donner A, Mueller BM, Ruf W. Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science 2002;296:1880-1882.
63. Cheng T, Liu D, Griffin JH, Fernandez JA, Castellino F, Rosen ED, Fukudome K, Zlokovic BV. Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective. Nat Med 2003;9:338-342.
64. Liu D, Cheng T, Guo H, Fernandez JA, Griffin JH, Song X, Zlokovic BV. Tissue plasminogen activator neurovascular toxicity is controlled by activated protein C. Nat Med 2004;10:1379-1383.
65. Isermann B, Vinnikov IA, Madhusudhan T, Herzog S, Kashif M, Blautzik J, Corat MA, Zeier M, Blessing E, Oh J, Gerlitz B, Berg DT, Grinnell BW, Chavakis T, Esmon CT, Weiler H, Bierhaus A, Nawroth PP. Activated protein C protects against diabetic nephropathy by inhibiting endothelial and podocyte apoptosis. Nat Med 2007;13:1349-1358.
66. Cheng T, Petraglia AL, Li Z, Thiyagarajan M, Zhong Z, Wu Z, Liu D, Maggirwar SB, Deane R, Fernandez JA, LaRue B, Griffin JH, Chopp M, Zlokovic BV. Activated protein C inhibits tissue plasminogen activator-induced brain hemorrhage. Nat Med 2006;12:1278-1285.
67. Feistritzer C, Riewald M. Endothelial barrier protection by activated protein C through PAR1-dependent sphingosine 1-phosphate receptor-1 cross-activation. Blood 2005;105:3178-3184.
68. Ikezoe T, Yang J, Nishioka C, Honda G, Furihata M, Yokoyama A. Thrombomodulin protects endothelial cells from a calcineurin inhibitor-induced cytotoxicity by upregulation of extracellular signal-regulated kinase/myeloid leukemia cell-1 signaling. Arterioscler Thromb Vasc Biol. 2012;32:2259-2270.
69. Ishii H, Salem HH, Bell CE, Laposata EA, Majerus PW. Thrombomodulin, an endothelial anticoagulant protein, is absent from the human brain. Blood. 1986;67:362-365.
70. Branson HE, Katz J, Marble R, Griffin JH. Inherited protein C deficiency and coumarin-responsive chronic relapsing purpura fulminans in a newborn infant. Lancet 1983;322:1165-1668.
71. Ohlin AK, Marlar RA. The first mutation identified in the thrombomodulin gene in a 45 year old man presenting with thromboembolic disease. Blood 1995;85:330-336.
72. Seligsohn U, Berger A, Abend M, Rubin L, Attias D, Zivelin A, Rapaport SI. Homozygous protein C deficiency manifested by massive venous thrombosis in the newborn. New Engl J Med 1984;310:559-562.
73. Laszik ZG, Zhou XJ, Ferrell GL, Silva FG, Esmon CT. Downregulation of endothelial expression of endothelial cell protein C receptor and thrombomodulin in coronary atherosclerosis. Am J Pathol 2001;159:797-802.
74. Faust SN, Levin M, Harrison OB, Goldin RD, Lockhart MS, Kondaveeti S, Laszik Z, Esmon CT, Heyderman RS. Dysfunction of endothelial protein C activation in severe meningococcal sepsis. N Engl J Med 2001;345:408-416.
75. Kim AY, Walinsky PL, Kolodgie FD, Bian C, Sperry JL, Deming CB, Peck EA, Shake JG, Ang GB, Sohn RH, Esmon CT, Virmani R, Stuart RS, Rade JJ. Early loss of thrombomodulin expression impairs vein graft thromboresistance: Implications for vein graft failure. Circ Res 2002; 90: 205-212.
76. Esmon CT. New mechanisms for vascular control of inflammation mediated by natural anticoagulant proteins. J Exp Med 2002;196:561-564.
77. Kume M, Hayashi T, Yuasa H, Tanaka H, Nishioka J, Ido M, Gabazza EC, Kawarada Y, Suzuki K. Bacterial lipopolysaccharide decreases thrombomodulin expression in the sinusoidal endothelial cells of rats-a possible mechanism of intrasinusoidal microthrombus formation and liver dysfunction. J Hepatol 2003;38:9-17.
78. Séguin C, Abid MR, Spokes KC, Aird WC. Thrombin downregulates thrombomodulin expression and activity in primary human endothelial cells. Endothelium 2008;15:143-148.
79. Boehme MW, Deng Y, Raeth U, Bierhaus A, Ziegler R, Stremmel W, Nawroth PP. Release of thrombomodulin from endothelial cells by concerted action of TNF-alpha and neutrophils: In vivo and in vitro studies. Immunology 1996;87:134-140.
80. Takahashi H, Hanano M, Wada K, Tatewaki W, Niwano H, Tsubouchi J, Nakano M, Nakamura T, Shibata A. Circulating thrombomodulin in thrombotic thrombocytopenic purpura. Am J Hematol 1991;38:174-177.
81. Tanaka A, Ishii H, Hiraishi S, Kazama M, Maezawa H. Increased thrombomodulin values in plasma of diabetic men with microangiopathy. Clin Chem 1991;37:269-272.
82. Takahashi H, Ito S, Hanano M, Wada K, Niwano H, Seki Y, Shibata A. Circulating thrombomodulin as a novel endothelial cell marker: Comparison of its behavior with von Willebrand factor and tissue-type plasminogen activator. Am J Hematol 1992;41:32-39.
83. Seigneur M, Dufourcq P, Conri C, Constans J, Mercié P, Pruvost A, Amiral J, Midy D, Baste JC, Boisseau MR. Levels of plasma thrombomodulin are increased in atheromatous arterial disease. Thromb Res 1993;71:423-431.
84. Lindahl AK, Boffa MC, Abildgaard U. Increased plasma thrombomodulin in cancer patients. Thromb Haemost 1993;69:112-114.
85. Ohdama S, Takano S, Miyake S, Kubota T, Sato K, Aoki N. Plasma thrombomodulin as a marker of vascular injuries in collagen vascular diseases. Am J Clin Pathol 1994;101:109-113.
86. Boffa MC, Lapeyrère C, Berard M, Lindahl AK, Flageul B, Chemaly P, Abildgaard U, Dubertret L. Plasma thrombomodulin level in malignancy varies according to the tumor type. Nouv Rev Fr Hematol 1994;36(Suppl 1):S87-S88.
87. Salmaggi A, Eoli M, Frigerio S, Ciusani E, Silvani A, Boiardi A. Circulating intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1) and plasma thrombomodulin levels in glioblastoma patients. Cancer Lett 1999;146:169-172.
88. Lin SM, Wang YM, Lin HC, Lee KY, Huang CD, Liu CY, Wang CH, Kuo HP. Serum thrombomodulin level relates to the clinical course of disseminated intravascular coagulation, multiorgan dysfunction syndrome, and mortality in patients with sepsis. Crit Care Med 2008;36:683-689.
89. Dittman WA, Majerus PW. Structure and function of thrombomodulin: A natural anticoagulant. Blood 1990;75:329-336.
90. Wu KK, Aleksic N, Ballantyne CM, Ahn C, Juneja H, Boerwinkle E. Interaction between soluble thrombomodulin and intercellular adhesion molecule-1 in predicting risk of coronary heart disease. Circulation 2003;107:1729-1732.
91. Tsiang M, Lentz SR, Dittman WA, Wen D, Scarpati EM, Sadler JE. Equilibrium binding of thrombin to recombinant human thrombomodulin: Effect of hirudin, fibrinogen, factor Va, and peptide analogs. Biochemistry 1990;29:10602-10612.
92. Lin JH, Mclean K, Morser J, Young TA, Wydro RM, Andrews WH, Light DR. Modulation of glycosaminoglycan addition in naturally expressed and recombinant human thrombomodulin. J Biol Chem 1994;269:25021-25030.
93. Gomi K, Zushi M, Honda G, Kawahara S, Matsuzaki O, Kanabayashi T, Yamamoto S, Maruyama I, Suzuki K. Antithrombotic effect of recombinant human thrombomodulin on thrombin-induced thromboembolism in mice. Blood 1990;75:1396-1399.
94. Aritomi M, Watanabe N, Ohishi R, Gomi K, Kiyota T, Yamamoto S, Ishida T, Maruyama I. Recombinant human soluble thrombomodulin delivers bounded thrombin to antithrombin III: Thrombomodulin associates with free thrombin and is recycled to activate protein C. Thromb Haemost 1993;70:418-422.
95. Mohri M, Suzuki M, Sugimoto E, Sata M, Yamamoto S, Maruyama I. Effects of recombinant human soluble thrombomodulin (rhs-TM) on clot-induced coagulation in human plasma. Thromb Haemost 1998;80:925-929.
96. Mohri M, Sugimoto E, Sata M, Asano T. The inhibitory effect of recombinant human soluble thrombomodulin on initiation and extension of coagulation-a comparison with other anticoagulants. Thromb Haemost 1999;82:1687-1693.
97. Mohri M, Gonda Y, Oka M, Aoki Y, Gomi K, Kiyota T, Sugihara T, Yamamoto S, Ishida T, Maruyama I. The antithrombotic effects of recombinant human soluble thrombomodulin (rhsTM) on tissue factor-induced disseminated intravascular coagulation in crab-eating monkeys (Macaca fascicularis). Blood Coagul Fibrinolysis 1997;8:274-283.
98. Mohri M, Oka M, Aoki Y, Gonda Y, Hirata S, Gomi K, Kiyota T, Sugihara T, Yamamoto S, Ishida T. Intravenous extended infusion of recombinant human soluble thrombomodulin prevented tissue factor-induced disseminated intravascular coagulation in rats. Am J Hematol 1994;45:298-303.
99. Aoki Y, Ohishi R, Takei R, Matsuzaki O, Mohri M, Saitoh K, Gomi K, Sugihara T, Kiyota T, Yamamoto S. Effects of recombinant human soluble thrombomodulin (rhs-TM) on a rat model of disseminated intravascular coagulation with decreased levels of plasma antithrombin-III. Thromb Haemost 1994;71:452-455.
100. Taoka Y, Okajima K, Uchiba M, Johno M. Neuroprotection by recombinant thrombomodulin. Thromb Haemost 2000;83:462-468.
101. Aoki Y, Takei R, Mohri M, Gonda Y, Gomi K, Sugihara T, Kiyota T, Yamamoto S, Ishida T, Maruyama I. Antithrombotic effects of recombinant human soluble thrombomodulin (rhs-TM) on arteriovenous shunt thrombosis in rats. Am J Hematol 1994;47:162-166.
102. Moll S, Lindley C, Pescatore S, Morrison D, Tsuruta K, Mohri M, Serada M, Sata M, Shimizu H, Yamada K, White GC 2nd. Phase I study of a novel recombinant human soluble thrombomodulin, ART-123. J Thromb Haemost. 2004;2:1745-1751.
103. Maruyama I. Recombinant thrombomodulin and activated protein C in the treatment of disseminated intravascular coagulation. Thromb Haemost 1999;82:718-721.
104. Saito H, Maruyama I, Shimazaki S, Yamamoto Y, Aikawa N, Ohno R, Hirayama A, Matsuda T, Asakura H, Nakashima M, Aoki N. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: Results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost 2007;5:31-41.
105. Okamoto T, Tanigami H, Suzuki K, Shimaoka M. Thrombomodulin: A bifunctional modulator of inflammation and coagulation in sepsis. Crit Care Res Pract 2012;2012:614545.
106. Kearon C, Comp P, Douketis J, Royds R, Yamada K, Gent M. Dose-response study of recombinant human soluble thrombomodulin (ART-123) in the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost 2005;3:962-968.
107. Ikezoe T, Togitani K, Komatsu N, Isaka M, Yokoyama A. Successful treatment of sinusoidal obstructive syndrome after hematopoietic stem cell transplantation with recombinant human soluble thrombomodulin. Bone Marrow Transplant 2010;45:783-785.
108. Sakai M, Ikezoe T, Bandobashi K, Togitani K, Yokoyama A. Successful treatment of transplantation-associated thrombotic microangiopathy with recombinant human soluble thrombomodulin. Bone Marrow Transplant 2010;45:803-805.
109. 2+. Eur J Biochem 1999;262:522-533.
110. Su EJ, Geyer M, Wahl M, Mann K, Ginsburg D, Brohmann H, Petersen KU, Lawrence DA. The thrombomodulin analog Solulin promotes reperfusion and reduces infarct volume in a thrombotic stroke model. J Thromb Haemost 2011;9:1174-1182.
111. Ryang YM, Dang J, Kipp M, Petersen KU, Fahlenkamp AV, Gempt J, Wesp D, Rossaint R, Beyer C, Coburn M. Solulin reduces infarct volume and regulates gene-expression in transient middle cerebral artery occlusion in rats. BMC Neurosci 2011;12:113.
112. Foley JH, Petersen KU, Rea CJ, Harpell L, Powell S, Lillicrap D, Nesheim ME, Sørensen B. Solulin increases clot stability in whole blood from humans and dogs with hemophilia. Blood 2012;119:3622-3628.
113. van Iersel T, Stroissnig H, Giesen P, Wemer J, Wilhelm-Ogunbiyi K. Phase I study of Solulin, a novel recombinant soluble human thrombomodulin analogue. Thromb Haemost 2011;105:302-312.
114. Villoutreix BO, Dahlback B. Molecular model for the C-type lectin domain of human thrombomodulin. J Mol Model 1998;4:310-322.
115. Kuo C, Chen P, Chang B, Sung M, Shi C, Lee J, Chang CF, Shi GY, Wu HL. The recombinant lectin-like domain of thrombomodulin inhibits angiogenesis through interaction with Lewis Y antigen. Blood 2012;119:1302-1313.
116. Abeyama K, Stern DM, Ito Y, Kawahara K, Yoshimoto Y, Tanaka M, Uchimura T, Ida N, Yamazaki Y, Yamada S, Yamamoto Y, Yamamoto H, Iino S, Taniguchi N, Maruyama I. The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel anti-inflammatory mechanism. J Clin Invest 2005;115:1267-1274.
117. Ito T, Kawahara K, Okamoto K, Yamada S, Yasuda M, Imaizumi H, Nawa Y, Meng X, Shrestha B, Hashiguchi T, Maruyama I. Proteolytic cleavage of high mobility group box 1 protein by thrombin-thrombomodulin complexes. Arterioscler Thromb Vasc Biol 2008;28:1825-1830.
118. Jin H, Yang X, Liu K, Gu Q, Xu X. Effects of a novel peptide derived from human thrombomodulin on endotoxin-induced uveitis in vitro and in vivo. FEBS Lett 2011;585:3457-3464.
119. Kurosawa S, Stearns DJ, Jackson KW, Esmon CT. A 10-kDa cyanogen bromide fragment from the epidermal growth factor homology domain of rabbit thrombomodulin contains the primary thrombin binding site. J Biol Chem 1988;263:5993-5996.
120. Rezaie AR, Esmon CT. The function of calcium in protein C activation by thrombin and the thrombin-thrombomodulin complex can be distinguished by mutational analysis of protein C derivatives. J Biol Chem 1992;267:26104-26109.
121. Parkinson JF, Nagashima M, Kuhn I, Leonard J, Morser J. Structure-function studies of the epidermal growth factor domains of human thrombomodulin. Biochem Biophys Res Commun 1992;185:567-576.
122. Esmon CT, Esmon NL, Harris KW. Complex formation between thrombin and thrombomodulin inhibits both thrombin-catalyzed fibrin formation and factor V activation. J Biol Chem 1982;257:7944-7947.
123. Ye J, Liu LW, Esmon CT, Johnson AE. The fifth and sixth growth factor-like domains of thrombomodulin bind to the anion-binding exosite of thrombin and alter its specificity. J Biol Chem 1992;267:11023-11028.
124. Hofsteenge J, Taguchi H, Stone SR. Effect of thrombomodulin on the kinetics of the interaction of thrombin with substrates and inhibitors. Biochem J 1986;237:243-251.
125. 2+-mediated binding to protein C. J Biol Chem 1991;266:19886-19889.
126. Zushi M, Gomi K, Yamamoto S, Maruyama I, Hayashi T, Suzuki K. The last three consecutive epidermal growth factor-like structures of human thrombomodulin comprise the minimum functional domain for protein C-activating cofactor activity and anticoagulant activity. J Biol Chem 1989;264:10351-10353.
127. White CE, Hunter MJ, Meininger DP, White LR, Komives EA. Large-scale expression, purification and characterization of small fragments of thrombomodulin: The roles of the sixth domain and of methionine 388. Protein Eng 1995;8:1177-1187.
128. Clarke JH, Light DR, Blasko E, Parkinson JF, Nagashima M, McLean K, Vilander L, Andrews WH, Morser J, Glaser CB. The short loop between epidermal growth factor-like domain 4 and domain 5 is critical for human thrombomodulin function. J Biol Chem 1993;268:6309-6315.
129. Suzuki M, Mohri M, Yamamoto S. In vitro anticoagulant properties of a minimum functional fragment of human thrombomodulin and in vivo demonstration of its benefit as an anticoagulant in extracorporeal circulation using a monkey model. Thromb Haemost 1998;79:244-455.
130. Schenk-Braat EA, Morser J, Rijken DC. Identification of the epidermal growth factor-like domains of thrombomodulin essential for the acceleration of thrombin-mediated inactivation of single-chain urokinase-type plasminogen activator. Eur J Biochem 2001;268:5562-5569.
131. Kishida A, Ueno Y, Fukudome N, Yashima E, Maruyama I, Akashi M. Immobilization of human thrombomodulin onto poly (ether urethane urea) for developing antithrombogenic blood-contacting materials. Biomaterials 1994;15:848-852.
132. Kishida A, Ueno Y, Maruyama I, Akashi M. Immobilization of human thrombomodulin onto biomaterials. Comparison of immobilization methods and evaluation of antithrombogenicity. ASAIO J 1994;40:M840-M845.
133. Vasilets VN, Hermel G, König U, Werner C, Müller M, Simon F, Grundke K, Ikada Y, Jacobasch HJ. Microwave CO2 plasma-initiated vapour phase graft polymerization of acrylic acid onto polytetrafluoroethylene for immobilization of human thrombomodulin. Biomaterials 1997;18:1139-1145.
134. Li JM, Singh MJ, Nelson PR, Hendricks GM, Itani M, Rohrer MJ, Cutler BS. Immobilization of human thrombomodulin to expanded polytetrafluoroethylene. J Surg Res 2002;105:200-208.
135. Sperling C, Salchert K, Streller U, Werner C. Covalently immobilized thrombomodulin inhibits coagulation and complement activation of artificial surfaces in vitro. Biomaterials 2004;25:5101-5113.
136. Han HS, Yang SL, Yeh HY, Lin JC, Wu HL, Shi GY. Studies of a novel human thrombomodulin immobilized substrate: Surface characterization and anticoagulation activity evaluation. J Biomater Sci Polym Ed 2001;12:1075-1089.
137. Cazalis CS, Haller CA, Sease-Cargo L, Chaikof EL. C-terminal site-specific PEGylation of a truncated thrombomodulin mutant with retention of full bioactivity. Bioconjug Chem 2004;15:1005-1009.
138. Sun XL, Stabler CL, Cazalis CS, Chaikof EL. Carbohydrate and protein immobilization onto solid surfaces by sequential Diels-Alder and azide-alkyne cycloadditions. Bioconjug Chem 2006;17:52-57.
139. Stabler CL, Sun XL, Cui W, Wilson JT, Haller CA, Chaikof EL. Surface re-engineering of pancreatic islets with recombinant azido-thrombomodulin. Bioconjug Chem 2007;18:1713-1715.
140. Wilson JT, Haller CA, Qu Z, Cui W, Urlam MK, Chaikof EL. Biomolecular surface engineering of pancreatic islets with thrombomodulin. Acta Biomater 2010;6:1895-1903.
141. Zhang H, Weingart J, Jiang R, Peng J, Wu Q, Sun XL. Bio-inspired liposomal thrombomodulin conjugate through bio-orthogonal chemistry. Bioconjug Chem 2013;24:550-559.
142. Jiang R, Weingart J, Zhang H, Ma Y, Sun XL. End-point immobilization of recombinant thrombomodulin via sortase-mediated ligation. Bioconjug Chem 2012;23:643-649.
143. Wang YX, Wu C, Vincelette J, Martin-McNulty B, Alexander S, Larsen B, Light DR, McLean K. Amplified anticoagulant activity of tissue factor-targeted thrombomodulin: In-vivo validation of a tissue factor-neutralizing antibody fused to soluble thrombomodulin. Thromb Haemost 2006;96:317-324.
144. Ding BS, Hong N, Christofidou-Solomidou M, Gottstein C, Albelda SM, Cines DB, Fisher AB, Muzykantov VR. Anchoring fusion thrombomodulin to the endothelial lumen protects against injury-induced lung thrombosis and inflammation. Am J Respir Crit Care Med 2009;180:247-256.
145. Zaitsev S, Kowalska MA, Neyman M, Carnemolla R, Tliba S, Ding BS, Stonestrom A, Spitzer D, Atkinson JP, Poncz M, Cines DB, Esmon CT, Muzykantov VR. Targeting recombinant thrombomodulin fusion protein to red blood cells provides multifaceted thromboprophylaxis. Blood 2012;119:4779-4785.
146. Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J, Frazier A, Yang H, Ivanova S, Borovikova L, Manogue KR, Faist E, Abraham E, Andersson J, Andersson U, Molina PE, Abumrad NN, Sama A, Tracey KJ. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999;285:248-251.
147. Yang H, Ochani M, Li J, Qiang X, Tanovic M, Harris HE, Susarla SM, Ulloa L, Wang H, DiRaimo R, Czura CJ, Wang H, Roth J, Warren HS, Fink MP, Fenton MJ, Andersson U, Tracey KJ. Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc Natl Acad Sci USA 2004;101:296-301.
148. Li Y, Gong W, Zhang L, Huang G, Li J, Shen X, He F. Expression and purification of the fusion protein HMGB1Abox-TMD1, a novel HMGB1 antagonist. Biochemistry (Mosc) 2010;75:466-471.